Avricore Health Inc. (TSXV: AVCR): Corporate Profile & Financials

By Raveendran R | Updated on: November 15, 2026

Source: Avricore Health Inc. Form 20-F 2025

Avricore Health Inc. is a Canadian healthcare technology and pharmacy service innovator focused on acquiring, developing, and commercializing disruptive point-of-care testing technologies designed to expand the clinical diagnostic capabilities of community pharmacies. Headquartered in Vancouver, British Columbia, the company operates primarily through its wholly owned subsidiary, HealthTab Inc., and its United Kingdom-based operating entity, HealthTab Ltd. By equipping community pharmacies with integrated, web-connected blood chemistry analyzers and proprietary diagnostic software, Avricore enables pharmacists to deliver rapid, laboratory-accurate biomarker testing directly to patients in a retail setting.

Core Business Segments & Operating Lines:
  • Healthtab™ – Point Of Care Business (Canada): Segment revenue: $497.07 K (93.11%).
  • Healthtab™ Uk – Point Of Care Business (United Kingdom): Segment revenue: $36.81 K (6.89%).
Metrics for FY 2025
Income Statement Metrics
Revenue
$533.88 K (▼ 88.8%)
Prev Year: $4.79 M
Gross Profit
$238.29 K (▼ 87.3%)
Prev Year: $1.88 M
Operating Profit
-$1.38 M (▼ 1172.4%)
Prev Year: $129.00 K
Net Profit
-$1.86 M (▼ 177.8%)
Prev Year: -$668.98 K
Gross Margin
44.63 % (▲ 534 bps)
Prev Year: 39.29 %
Operating Margin
-259.13 % (▼ 26183 bps)
Prev Year: 2.70 %
PAT Margin
-348.16 % (▼ 33418 bps)
Prev Year: -13.98 %
Asset Turnover
0.95x (▼ 1.13 pts)
Prev Year: 2.08x
Return & Capital Efficiency Metrics
ROE
-477.14 % (▼ 44314 bps)
Prev Year: -34.00 %
ROCE
-355.13 % (▼ 36169 bps)
Prev Year: 6.56 %
ROC
-355.13 % (▼ 36169 bps)
Prev Year: 6.56 %
ROA
-330.08 % (▼ 30097 bps)
Prev Year: -29.10 %
Cash ROE
-202.77 % (▼ 25383 bps)
Prev Year: 51.05 %
Cash ROCE
-202.77 % (▼ 25383 bps)
Prev Year: 51.05 %
Cash ROC
-202.77 % (▼ 25383 bps)
Prev Year: 51.05 %
Cash ROA
-140.28 % (▼ 18398 bps)
Prev Year: 43.71 %
3Y Avg ROE
-182.26 %
3Y Avg ROCE
-127.94 %
3Y Avg ROC
-127.94 %
3Y Avg ROA
-129.90 %
Balance Sheet Metrics
Total Assets
$563.12 K (▼ 75.5%)
Prev Year: $2.30 M
Current Assets
$366.33 K (▼ 76.9%)
Prev Year: $1.58 M
Total Liabilities
$173.56 K (▼ 47.5%)
Prev Year: $330.82 K
Current Liabilities
$173.56 K (▼ 47.5%)
Prev Year: $330.82 K
Capital Employed
$389.56 K (▼ 80.2%)
Prev Year: $1.97 M
Total Equity
$389.56 K (▼ 80.2%)
Prev Year: $1.97 M
Working Capital
$192.77 K (▼ 84.6%)
Prev Year: $1.25 M
Current Ratio
2.11x (▼ 2.67 pts)
Prev Year: 4.78x
Equity Multiplier
1.45x (▲ 0.28 pts)
Prev Year: 1.17x
Cash Flow Metrics
Operating Cash Flow
-$789.93 K (▼ 178.6%)
Prev Year: $1.00 M
CapEx
$114.36 K (▼ 44.3%)
Prev Year: $205.35 K
Free Cash Flow
-$904.29 K (▼ 213.1%)
Prev Year: $799.27 K
OCF Margin
-147.96 % (▼ 16895 bps)
Prev Year: 20.99 %
FCF Margin
-169.38 % (▼ 18608 bps)
Prev Year: 16.70 %

📋 Quick Facts / Company Snapshot: Avricore Health Inc.V

Data Point Disclosed Detail
Official Company Name Avricore Health Inc.
Ticker Symbol (TSX Venture Exchange) AVCR
Ticker Symbol (OTCQB / Pink Sheets) AVCRF
SEC Central Index Key (CIK) 0001355736
SEC Commission File Number 000-51848
Primary Exchange TSX Venture Exchange (TSXV)
U.S. Quotation Venue OTCQB / Pink Sheets
Principal Executive Offices 1120 – 789 West Pender Street, Vancouver, British Columbia, V6C 1H2, Canada
Registered Corporate Office 700 – 1199 West Hastings Street, Vancouver, British Columbia, V6E 3T5, Canada
Jurisdiction of Incorporation British Columbia, Canada
Date of Incorporation May 30, 2000
Corporate Form Predecessor Duft Biotech Capital Ltd. (Classified as a Capital Pool Company)
Industry / Sector Health Data and Point-of-Care Technologies (POCT) / Pharmacy Services
Total Full-Time Employees 1 (as of December 31, 2025; Executive leadership engaged via consulting agreements)
Chief Executive Officer Rodger Seccombe (Appointed June 4, 2025)
Chief Financial Officer & Corporate Secretary Kiki Smith
Chairman of the Board of Directors David Hall
Principal Legal Subsidiaries HealthTab Inc., HealthTab Ltd.
Independent Auditor Manning Elliott LLP (Chartered Professional Accountants, Vancouver, Canada)
Transfer Agent & Registrar Computershare Trust Company of Canada

1. Corporate Identity: Avricore Health Inc.V Overview & History

The Big Picture

Avricore Health Inc. is a Canadian healthcare technology and pharmacy service innovator focused on acquiring, developing, and commercializing disruptive point-of-care testing technologies designed to expand the clinical diagnostic capabilities of community pharmacies. Headquartered in Vancouver, British Columbia, the company operates primarily through its wholly owned subsidiary, HealthTab Inc., and its United Kingdom-based operating entity, HealthTab Ltd. By equipping community pharmacies with integrated, web-connected blood chemistry analyzers and proprietary diagnostic software, Avricore enables pharmacists to deliver rapid, laboratory-accurate biomarker testing directly to patients in a retail setting.

The company’s strategic model addresses structural economic pressures confronting traditional retail pharmacies, where regulatory shifts, drug pricing caps, and dispensing margin compression have driven store owners to seek supplemental high-margin revenue streams. Through point-of-care testing, Avricore bridges community pharmacy infrastructure with preventative clinical diagnostics, providing rapid testing for critical metabolic and cardiovascular conditions.

  • Flagship Offering: HealthTab™ turnkey point-of-care testing platform.
  • Testing Turnaround Time: Delivery of laboratory-accurate diagnostic results within 12 minutes from a finger-prick blood sample.
  • Clinical Scope: Capability to screen and monitor up to 27 distinct biological markers, including comprehensive lipid profiles, liver health, kidney function, and HbA1c for diabetes.
  • Target Markets: Community pharmacy networks across Canada and the United Kingdom, partnering directly with primary care health trusts and international diagnostics manufacturers.

The Founders & Their Legacy

The technical architecture and operational foundations of Avricore’s operational engine trace back to HealthTab Inc., which was co-founded by Rodger Seccombe. Prior to creating HealthTab, Seccombe accumulated over two decades of enterprise experience across software development, clean energy, and healthcare information technology. His background included designing cloud-based informatics infrastructures utilized by diagnostic medical laboratories and analytical instrument manufacturers, alongside early-stage venture leadership at Canadian Bioenergy Corporation beginning in 2006.

Recognizing that community pharmacies were underutilized primary healthcare access points, Seccombe and the founding HealthTab team developed an integrated ecosystem combining clinical-grade hardware with direct-to-consumer digital portals and electronic medical record interfaces. This platform was integrated into Avricore Health Inc. via a corporate acquisition completed in late 2017, ultimately positioning Seccombe to take over corporate leadership as Chief Executive Officer in June 2025.

The Journey: History & Evolution

Avricore Health Inc. was originally incorporated under the Company Act of British Columbia on May 30, 2000, under the name Duft Biotech Capital Ltd. Formed initially as a Capital Pool Company on the TSX Venture Exchange, its statutory mandate was to identify and evaluate early-stage operating businesses or corporate assets to complete a Qualifying Transaction under TSXV regulatory frameworks.

The company underwent several distinct corporate reorganizations, operational pivots, and strategic transformations over the subsequent two and a half decades:

  • November 13, 2003: Duft Biotech Capital Ltd. completed its Qualifying Transaction by acquiring the underlying assets of ALDA Pharmaceuticals Inc., an infection-control private enterprise established in 1996.
  • November 26, 2003: The corporate identity changed to ALDA Pharmaceuticals Corp., focusing on commercial and consumer antimicrobial formulations, preclinical pharmaceutical development, and hand sanitizers.
  • August 19, 2005: Shareholder and regulatory approvals expanded the company’s authorized capital structure to an unlimited number of common shares without par value.
  • Fiscal Year 2012: Management formally discontinued the manufacturing and commercialization of its historic T36 Antiseptic Hand Sanitizer product lines.
  • July 24, 2013: The corporation adopted the name NUVA Pharmaceuticals Inc. to reflect expanded life sciences development objectives.
  • July 28, 2014: The company rebranded as VANC Pharmaceuticals Inc., focusing on generic pharmaceuticals and over-the-counter therapeutic products.
  • December 28, 2017: VANC Pharmaceuticals completed the strategic acquisition of 100% of the issued and outstanding share capital of HealthTab Inc., securing ownership of its core point-of-care intellectual property, software platforms, and proprietary trade marks.
  • November 5, 2018: The issuer enacted its final corporate name change to Avricore Health Inc.
  • Fiscal Year 2019: Management formally wound down and discontinued its legacy generic and over-the-counter pharmaceutical manufacturing business, dedicating 100% of operational resources to the HealthTab point-of-care platform.
  • Fiscal Years 2022–2024: Avricore deployed the HealthTab platform across an extensive Canadian commercial footprint, rolling out 776 network analyzers to Shoppers Drug Mart and affiliated Loblaw pharmacy locations nationwide.
  • March 31, 2025: The master commercial agreement with Shoppers Drug Mart expired without renewal, prompting Avricore to initiate the immediate staging, asset recovery, and redeployment of more than 700 analyzers from Canada to target National Health Service pharmacy pilots across the United Kingdom.

The Corporate Umbrella

Avricore Health Inc. serves as the ultimate parent company and holding entity for the consolidated group. The operational business is segmented across two legal layers: the Canadian parent holding entity and two operating subsidiaries.

The corporate structure consists of:

  • Avricore Health Inc. (Parent Holding Company): Incorporated in British Columbia, Canada; listed on the TSXV (AVCR) and quoted on OTCQB (AVCRF).
  • HealthTab Inc. (Wholly Owned Direct Subsidiary): Incorporated under the laws of British Columbia, Canada; holds core intellectual property, proprietary software assets, and North American operational assets.
  • HealthTab Ltd. (Wholly Owned Indirect Operating Subsidiary): Incorporated under the laws of the United Kingdom; operating arm responsible for UK commercial rollouts, clinical trial network partnerships, and NHS-linked pharmacy distribution agreements.

2. The Business Engine: Avricore Health Inc.V Business Model & Revenue Segments

The Core Divisions

Avricore operates in a single reportable corporate segment: health data and point-of-care technologies. The operational focus of this business engine revolves around providing turn-key diagnostic testing packages to retail pharmacies, comprised of hardware installation, proprietary cloud software, clinical reagent supply chains, and consumer interface connectivity.

Financially and operationally, management tracks revenue generation across two geographic components of its point-of-care business: Canadian operations and United Kingdom operations.

Business Segment / Operational Division 2025 Revenue ($) 2024 Revenue ($) 2023 Revenue ($) Latest YoY (%)
HealthTab™ – Point of Care Business (Canada)
497,074 4,785,711 3,485,147 -89.61%
HealthTab™ UK – Point of Care Business (United Kingdom)
36,810 0 0 N/M

The Canadian operating division generated the vast majority of historical gross revenue under a national enterprise lease model. The sharp contraction observed in 2025 highlights the conclusion of Canadian corporate chain deployments following the expiration of the Shoppers Drug Mart agreement on March 31, 2025. Conversely, the United Kingdom operational division entered active commercial service during fiscal 2025, laying the groundwork for clinical pilot integrations across National Health Service networks.

The Global Product Catalog

The company’s product and service architecture is anchored by the HealthTab™ ecosystem. Unlike traditional laboratory diagnostic pathways that require off-site phlebotomy, venous draws, cold-chain transport, and multi-day waiting periods, HealthTab establishes an on-site micro-laboratory within community pharmacies.

The functional components of the HealthTab product catalog comprise:

  • Hardware Diagnostic Systems: The deployment of clinical chemistry analyzers (such as the Abbott Afinion™ 2 Analyzer) coupled with dedicated on-site computer terminals, peripheral interfaces, and secured networking equipment.
  • Rapid Finger-Stick Diagnostic Chemistry: Test panels requiring only a small capillary blood sample obtained via a patient-assisted finger prick. The platform generates quantitative clinical results within 12 minutes.
  • Proprietary Cloud-Based Software: A software ecosystem that captures analyzer diagnostic readings, processes algorithmic metrics, and synchronizes clinical records with hospital and primary care databases.
  • Patient and Clinician Portals: A secure digital communication system that provides consumers with direct online access to their historical health profiles while allowing pharmacists and attending general practitioners to track chronic disease markers.
  • De-Identified Real-World Data Engines: Systems designed to aggregate anonymized patient population metrics, providing clinical research entities and pharmaceutical manufacturers with real-time therapeutic monitoring data.

The Names You Know

Avricore’s operational portfolio centers around established proprietary trademarks alongside co-marketing arrangements with major medical diagnostics brands:

  • HealthTab™: The registered flagship brand encompassing the cloud-connected hardware suite, diagnostic software, and turnkey point-of-care clinical platform.
  • Abbott Afinion™ 2: Diagnostic analyzer distributed by HealthTab Ltd. under a formal multi-year UK commercial collaboration agreement with Abbott Rapid Diagnostics Limited UK & Ireland, specifically testing for glycated hemoglobin (HbA1c) and comprehensive lipid panels.
  • Discontinued Historic Brands: Legacy trademarks previously retained from historical corporate combinations include T36 (discontinued hand sanitizer product lines), Corozon, and Emerald.

Mapping the Global Reach

Avricore manages geographic operations across North America and Western Europe, with corporate headquarters located in Canada and commercial field expansion active in the United Kingdom.

Geographic Market 2025 Revenue ($) 2024 Revenue ($) 2023 Revenue ($) Latest YoY (%)
Canada
497,074 4,785,711 3,485,147 -89.61%
United Kingdom
36,810 0 0 N/M
Total Consolidated Revenue 533,884 4,785,711 3,485,147 -88.84%

The geographic transition of revenue reflects an active operational pivot. Canadian revenue contracted by 89.61% in fiscal 2025 following the termination of operations with Shoppers Drug Mart. In response, the company staged and shipped over 700 analyzers from Canada directly into the UK market. The UK operational unit booked its initial $36,810 of revenue in 2025, operating across National Health Service clinical pilots in North East London, North Central London, and regional areas outside London.

The Brick & Mortar Footprint

Avricore maintains an asset-light corporate property footprint, operating through leased executive and administrative offices in Vancouver, British Columbia:

  • Principal Executive Offices: Suite 1120 – 789 West Pender Street, Vancouver, BC, V6C 1H2, Canada.
  • Registered Corporate & Records Office: Suite 700 – 1199 West Hastings Street, Vancouver, BC, V6E 3T5, Canada.
  • Pharmacy Equipment Deployments: Physical assets do not consist of real property, but rather technical diagnostic infrastructure deployed directly within retail partner stores. As of December 1, 2025, the company had 38 HealthTab™ systems actively operating in the UK (7 in North East London, 6 in North Central London, and 25 across regional pharmacies outside London), alongside staging facilities holding recovered analyzer hardware.

3. The Financial Health: Avricore Health Inc.V (FY 2025) Audited Financial Statements

Earnings, Expenses & Profits: Avricore Health Inc.V Income Statement

Avricore’s operational performance in fiscal 2025 was defined by the termination of its master commercial deployment agreement with its primary retail customer on March 31, 2025. This contract conclusion resulted in an 88.85% year-over-year decline in top-line revenue, which dropped from $4,785,711 in fiscal 2024 to $533,884 in fiscal 2025. Gross profit declined from $1,880,287 in 2024 to $238,295 in 2025.

Compounding operational revenue reductions, the company conducted comprehensive impairment evaluations across its operating asset base, writing down idle hardware and system software by a combined $493,544. Operating expenses for the period totaled $1,621,759, yielding a consolidated net loss of $1,858,747 for the year ended December 31, 2025.

Consolidated Statement of Operations Line Item (in CAD $) 2025 2024 2023 Latest YoY (%)
Revenue 533,884 4,785,711 3,485,147 -88.84%
Cost of sales -295,589 -2,905,424 -2,281,751 -89.83%
Gross profit 238,295 1,880,287 1,203,396 -87.33%
Advertising and promotion 0 0 -1,035 N/M
Amortization -1,967 -3,137 -2,347 -37.30%
Consulting -320,640 -276,000 -236,117 +16.17%
General and administrative -467,326 -409,398 -339,369 +14.15%
Management fees -90,000 -216,000 -216,000 -58.33%
Shareholder communications -41,954 -49,932 -112,234 -15.98%
Professional fees -311,195 -255,655 -285,935 +21.72%
Severance benefits -108,000 0 0 N/M
Share-based compensation -280,677 -541,164 -703,612 -48.13%
Income (Loss) before other income (expense) -1,383,464 129,001 -693,253 N/M
Foreign exchange gain (loss) -764 -5,006 -6,652 -84.74%
Interest income 12,124 1,235 3,284 +881.70%
Loss on impairment of equipment -422,950 -772,174 0 -45.23%
Loss on impairment of intangible assets -70,594 0 0 N/M
Loss on disposal of equipment 0 -32,033 0 -100.00%
Recovery (write-off) of accounts receivable 6,901 0 -4,594 N/M
Gain on settlement of loan 0 10,000 0 -100.00%
Net loss for the year -1,858,747 -668,977 -701,215 +177.85%
Foreign currency translation -93 -47 0 +97.87%
Comprehensive loss for the year -1,858,840 -669,024 -701,215 +177.84%

The operational cost structure revealed targeted management realignments following the contract expiration. Amortization booked under cost of sales fell from $446,474 in 2024 to $137,648 in 2025 as equipment bases were written down. Direct reagent procurement costs collapsed from $1,787,574 in 2024 to $44,852 in 2025, mirroring reduced retail testing volume in Canada. General and administrative expenses grew from $409,398 in 2024 to $467,326 in 2025, driven by international travel outlays of $93,203 and office lease expenditures of $69,023 related to establishing the UK corporate presence.

Assets, Debts & Equity: Avricore Health Inc.V Balance Sheet

As of December 31, 2025, Avricore reported total consolidated assets of $563,125, representing a 75.50% reduction from total assets of $2,298,544 recorded at the close of fiscal 2024. The asset contraction stemmed from operating cash consumption and structural impairment charges recorded against technical point-of-care hardware and associated system software.

Working capital closed the fiscal year at $192,772, down from $1,252,139 in 2024. The company maintains an unencumbered corporate debt profile, having discharged its government pandemic emergency loans in January 2024.

Consolidated Statement of Financial Position Line Item (in CAD $) December 31, 2025 December 31, 2024 Latest YoY (%)
Cash and cash equivalents 227,918 1,132,392 -79.87%
Term deposit 10,000 10,000 0.00%
Accounts receivable 37,332 419,587 -91.10%
Prepaid expenses and deposits 91,083 20,470 +344.96%
Inventory 0 507 -100.00%
Total Current Assets 366,333 1,582,956 -76.86%
Equipment 196,789 656,441 -70.02%
Intangible assets 3 59,147 -99.99%
Total Assets 563,125 2,298,544 -75.50%
Accounts payable and accrued liabilities 173,561 330,817 -47.54%
Total Current Liabilities 173,561 330,817 -47.54%
Total Liabilities 173,561 330,817 -47.54%
Share capital 27,304,793 27,304,793 0.00%
Reserves 7,348,195 7,067,518 +3.97%
Accumulated other comprehensive loss -140 -47 +197.87%
Deficit -34,263,284 -32,404,537 +5.74%
Total Equity 389,564 1,967,727 -80.20%
Total Liabilities and Equity 563,125 2,298,544 -75.50%

The company’s capital reserves shifted during fiscal 2025 due to option and warrant expiries. A warrant reserve balance of $901,229 expired unexercised and was transferred directly to contributed surplus. Additionally, $4,219,875 of expired and cancelled incentive stock options was reclassified from option reserve into contributed surplus, leaving closing equity at $389,564.

Cash Flow & Capital Allocation: Avricore Health Inc.V Cash Flow Statement

Cash and cash equivalents fell by $904,474 on a net basis during the year ended December 31, 2025, ending the period at $227,918. Operating activities consumed $789,933 in net cash, reversing positive operational cash generation of $1,004,615 achieved during fiscal 2024.

Investing outlays were constrained to targeted hardware modifications and localized software enhancements to configure HealthTab analyzers for UK electronic medical record integrations.

Consolidated Statement of Cash Flows Line Item (in CAD $) 2025 2024 2023 Latest YoY (%)
Net loss -1,858,747 -668,977 -701,215 +177.85%
Amortization 139,615 450,196 420,067 -68.99%
Share-based compensation 280,677 541,164 703,612 -48.13%
Gain on settlement of loan 0 -10,000 0 -100.00%
(Recovery) / write off of accounts receivable -6,901 0 4,594 N/M
Loss on impairment of equipment 422,950 772,174 0 -45.23%
Loss on impairment of intangible assets 70,594 0 0 N/M
Loss on disposal of fixed assets 0 32,033 0 -100.00%
Change in accounts receivable 389,156 8,102 338,090 +4703.21%
Change in inventory 507 20,169 -20,676 -97.49%
Change in prepaid expenses and deposits -70,613 18,155 -8,394 N/M
Change in deferred revenue 0 0 -252,000 N/M
Change in accounts payable and accrued liabilities -157,171 -158,401 176,325 -0.78%
Net cash provided by (used in) operating activities -789,933 1,004,615 660,403 N/M
Investment in intangible asset (software) -25,865 -24,253 -25,288 +6.65%
Purchase of equipment -88,497 -181,094 -1,021,571 -51.13%
Net cash used in investing activities -114,362 -205,347 -1,046,859 -44.31%
Proceeds from exercise of stock options 0 86,600 42,500 -100.00%
Loan repayments 0 -30,000 0 -100.00%
Net cash provided by financing activities 0 56,600 42,500 -100.00%
Increase (decrease) in cash and cash equivalents -904,295 855,868 -343,956 N/M
Effects of foreign exchange translation on cash -179 -47 0 +280.85%
Cash and cash equivalents, beginning of year 1,132,392 276,571 620,527 +309.44%
Cash and cash equivalents, end of year 227,918 1,132,392 276,571 -79.87%

The operational cash burn was mitigated by the collection of trade receivables accumulated under the prior Canadian commercial contracts, generating $389,156 in cash inflows from working capital. In total, operating cash outflows and capital additions consumed $904,295 before foreign exchange impacts of -$179.

Funding the Future: R&D and Expansion Spending

Avricore has phased out historical capital allocations toward clinical pharmaceutical development, pre-clinical trials, and patent filings. As disclosed in corporate filings, the enterprise no longer devotes capital resources to standalone drug research and development or traditional intellectual property patenting.

Capital deployment is dedicated to expanding the point-of-care testing footprint. On June 16, 2026, the company completed a post-period-end non-brokered private placement equity financing to replenish working capital reserves:

  • Gross Equity Proceeds: $1,254,000 raised via the issuance of 25,080,000 units priced at $0.05 per unit.
  • Unit Structure: Each unit comprised one common share and one-half of one transferable share purchase warrant, exercisable at $0.10 for two years.
  • Transaction Issuance Costs: $91,494, including $54,600 in cash finder fees and $27,355 representing the fair value of 1,092,000 finders’ warrants exercisable at $0.05.

4. The Corporate Family Tree: Avricore Health Inc.V Subsidiaries & Acquisitions

Subsidiaries, Associates, & Shared Ventures

Avricore Health Inc. operates through a streamlined, multi-tier corporate subsidiary structure designed to ring-fence operational liabilities and facilitate regional jurisdictional compliance:

  • HealthTab Inc. (British Columbia, Canada): Wholly owned direct subsidiary acquired on December 28, 2017. HealthTab Inc. holds the proprietary trademarks, cloud architecture designs, and core point-of-care intellectual property.
  • HealthTab Ltd. (United Kingdom): Wholly owned direct operating subsidiary of HealthTab Inc., incorporated in England and Wales. HealthTab Ltd. serves as the primary corporate operating contracting party for NHS community pharmacy initiatives, regional clinical trusts, and European equipment distribution contracts.

5. Power & Control: Avricore Health Inc.V Executive Leadership & Ownership

The Brain Trust: Board of Directors & Executive Leadership

Avricore Health Inc. is governed by an executive management team and independent Board of Directors possessing extensive experience across retail pharmacy management, regulatory compliance, corporate governance, and life sciences commercialization.

  • Rodger Seccombe (Chief Executive Officer & Director): Appointed CEO on June 4, 2025, Mr. Seccombe is the co-founder of HealthTab Inc. He brings more than 20 years of experience launching and leading commercial ventures across healthcare technology, software engineering, and renewable energy. A Chartered Professional Accountant (CPA-CMA), Seccombe holds a Bachelor of Commerce (Honours) from the Sauder School of Business at the University of British Columbia. Prior to HealthTab, he developed cloud informatics systems for diagnostic laboratories and co-founded startup operations at Canadian Bioenergy Corporation.
  • Kiki Smith, CPA, CGA (Chief Financial Officer & Corporate Secretary): Ms. Smith brings over two decades of capital markets and corporate administration experience across junior listed technology, mining exploration, and agri-food companies. Her background encompasses public equity financings, regulatory compliance, corporate structuring, and cash flow forecasting. She holds a Bachelor of Arts in Economics from the University of British Columbia and is a Certified Professional Accountant in British Columbia.
  • David Hall (Chairman of the Board & Director): Chairman of Avricore Health Inc., Chairman of 0913693 B.C. Ltd. (formerly RepliCel Life Sciences Inc.), and past Chairman of the Providence Healthcare Research Institute. Mr. Hall served as CEO and President of RepliCel from 2012 to 2015 and was a co-founder, Chief Financial Officer, Treasurer, and Chief Compliance Officer of Angiotech Pharmaceuticals Inc., which traded on NASDAQ and the TSX. He holds Honours degrees in Economics and Finance from the University of Manitoba.
  • Alan Arnstein (Independent Director): Mr. Arnstein previously served in corporate development for the Katz Group Canada, where he managed the store rollout of The Medicine Shoppe from 28 retail stores to 175 corporate and franchised locations prior to its corporate acquisition by McKesson Canada. He was instrumental in expanding the Rexall brand across Canada and leads real estate commercialization for the $5.5 billion ICE District development in Edmonton.
  • Dr. Robert Sindelar, Ph.D. (Independent Director): Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia and Advisor to the Centre for Health Evaluation & Outcomes Sciences at Providence Health Care Research Institute. Dr. Sindelar is an elected Fellow of the International Pharmaceutical Federation (FIP), Chair of the FIP Global Pharmacy Observatory Advisory Board, and past Dean of UBC’s Faculty of Pharmaceutical Sciences. He holds a Ph.D. in Medicinal Chemistry and Natural Products from the University of Iowa.
  • Christine Hrudka, ICD.D (Independent Director): Canadian retail pharmacist, healthcare executive, and former Chair of the Canadian Pharmacists Association. Ms. Hrudka previously owned and operated multiple Shoppers Drug Mart franchise locations in Saskatchewan as well as independent community pharmacies in Saskatoon. She sits on the Board of Directors of Rapid Dose Therapeutics Inc. and holds a B.Sc. in Pharmacy along with the Institute of Corporate Directors certification.
  • Tom Teahen (Independent Director): Former President and Chief Executive Officer of the Ontario Workplace Safety and Insurance Board (WSIB) from 2015 to 2021. Mr. Teahen served as Chief of Staff to the Ontario Minister of Labour, Minister of Education, and to the Office of the Premier of Ontario between 2005 and 2015. He currently serves as Senior Vice President of Advanced Fuels for Greenfield Global.

Who Owns the Stock?

Avricore’s share capital structure consists exclusively of common shares without par value, each conferring identical voting rights. As of December 31, 2025, there were 101,289,664 common shares outstanding. Following the closure of a private placement on June 16, 2026, issued share capital expanded to 126,369,664 common shares.

Beneficial Owner Common Shares Owned Options & Warrants Held Undiluted Ownership Share (%)
Rodger Seccombe (CEO & Director) 7,480,611 3,225,000 options / 1,300,000 warrants 5.92%
David Hall (Chairman of the Board) 1,343,618 1,750,000 options 1.06%
Kiki Smith (CFO & Corporate Secretary) 1,224,500 1,041,300 options / 200,000 warrants 0.97%
Dr. Robert Sindelar (Director) 915,000 975,000 options / 150,000 warrants 0.72%
Christine Hrudka (Director) 522,500 850,000 options / 250,000 warrants 0.41%
Tom Teahen (Director) 200,000 850,000 options / 100,000 warrants 0.16%
Alan Arnstein (Director) 25,000 975,000 options 0.02%
Total Directors & Senior Management 11,711,229 9,666,300 options / 2,000,000 warrants 9.27%

As of October 28, 2026, shareholder registry records indicated 64 registered holders of record, distributed geographically across Canada (57 registered holders), the United States (2 registered holders), and foreign jurisdictions including Switzerland, Hong Kong, the United Kingdom, and Bermuda (5 registered holders).

6. Strategic Outlook: Avricore Health Inc.V Growth Catalysts & Key Risks

Competitive Advantages & Economic Moats

Avricore’s competitive posture in community pharmacy point-of-care diagnostics relies on several core operational characteristics:

  • Proprietary Cloud Middleware Integration: The HealthTab system avoids operating as an isolated analytical bench device by connecting directly with NHS digital architecture, hospital registries, and primary care electronic medical record pathways.
  • Hardware-Agnostic Commercial Partnerships: Through formal distribution agreements with medical equipment developers like Abbott Rapid Diagnostics, Avricore integrates proven analytical platforms (such as the Afinion™ 2) rather than absorbing internal instrumentation development overhead.
  • Extensive Operational Testing Track Record: Having deployed across 776 Canadian retail pharmacies and screened thousands of patients within early-stage UK clinical cohorts, Avricore possesses proven protocols for pharmacist training, quality control validation, and biological waste compliance.
  • Low Capital Deployment Barrier: The redeployment of more than 700 fully depreciated and operational analyzers from Canada to the UK allows HealthTab Ltd. to expand regional pilots without incurring substantial initial capital expenditures for new diagnostic instrumentation.

What Could Go Wrong? Key Challenges & Business Risks

Avricore operates subject to significant commercial, liquidity, and operational risk factors detailed in its annual disclosures:

  • Going Concern and Working Capital Uncertainty: The company experienced recurring net losses, negative operating cash flows of $789,933 in 2025, and a working capital balance of $192,772 at year-end. Continuation of commercial operations depends on expanding operational cash generation and securing external equity or debt financing.
  • Extreme Customer Concentration and Revenue Volatility: The expiration of the master commercial rollout agreement with Shoppers Drug Mart on March 31, 2025, removed over 88% of consolidated revenue, illustrating the operational risk of commercial reliance on a single primary counterparty.
  • Regulatory and Prescribing Shifts in the UK: The company’s growth model in the UK depends on NHS execution of independent prescribing frameworks, pharmacy funding packages, and national diagnostic service rollouts. Regulatory delays or changes in NHS reimbursement tariffs could impact expansion.
  • Cybersecurity and Health Data Protection: Because the HealthTab software processes, transmits, and archives confidential biomarker data, any security breach, unauthorized access, or telecommunications interruption could result in legal liability, regulatory sanctions, and platform operational bans.
  • Penny Stock Regulations and U.S. Market Liquidity: With shares quoted over the counter under AVCRF, trading liquidity is limited in the United States and remains subject to Exchange Act Rule 15g-9 penny stock restrictions, which constrain broker-dealer recommendations.

The Next Chapter: Growth & Expansion Initiatives

Avricore’s corporate strategy centers on capturing market share across the United Kingdom pharmacy sector, driven by supportive structural shifts within the National Health Service:

  • UK National Prescribing Mandate: On May 29, 2026, the Department of Health and Social Care and NHS England announced a £340 million government-funded package for community pharmacy in 2026–2027, commissioning NHS-funded Independent Prescribing nationally from autumn 2026. This allows qualified community pharmacists to diagnose and prescribe directly for chronic cardiovascular conditions, requiring point-of-care biomarker screening infrastructure.
  • Targeted Lipid Screening with Barts Health NHS Trust: HealthTab has screened more than 3,500 patients across North East and North Central London community pharmacies in collaboration with Barts Health NHS Trust. In an initial cohort of 556 patients, one in five was identified as having elevated cardiovascular risk, validating the clinical utility of community-based lipid checks.
  • HbA1c Diabetes Testing Pilot: During an initial one-month screening pilot, the platform completed 2,295 HbA1c tests across 57 retail locations, achieving an average per-location testing volume 10 times higher than prior Canadian baseline figures.
  • Inclisiran Cholesterol Management Initiative: HealthTab is integrated into a secondary-prevention cardiovascular pilot directed by Barts Health NHS Trust, UCLPartners, and the British Heart Foundation, utilizing pharmacy testing to deliver novel inclisiran cholesterol-lowering therapies.

The Verdict: Strategic Outlook & Conclusion

Avricore Health Inc. is executing a fundamental operational repositioning. Having closed its long-standing Canadian retail chapter, the company is redirecting its technical assets toward the United Kingdom, where public policy and primary care budget allocations actively incentivize community pharmacies to perform clinical diagnostic screening. The success of this strategic transition will depend on converting UK regional pilots into long-term commercial software and reagent supply agreements, managing working capital constraints, and demonstrating sustained operational execution under its new executive leadership.

❓ Frequently Asked Questions: Avricore Health Inc.V

What was Avricore Health Inc.V’s revenue and net income in FY 2025?

In FY 2025, Avricore Health Inc.V reported total revenue of $533.88 K (▼ 88.8% compared to $4.79 M in the prior fiscal year). Gross profit stood at $238.29 K (gross margin of 44.63 %). Operating profit was -$1.38 M and bottom-line net income was -$1.86 M.

Is Avricore Health Inc.V profitable and generating positive cash flow in FY 2025?

In FY 2025, Avricore Health Inc.V reported a net loss of -$1.86 M (PAT margin: -348.16 %). On a cash basis, the company generated -$789.93 K in cash flow from operating activities and invested $114.36 K in capital expenditures, resulting in free cash flow of -$904.29 K. Return on Equity (ROE) was -477.14 % and Cash ROE was -202.77 %.

How much debt, assets, and equity does Avricore Health Inc.V hold?

As of FY 2025, Avricore Health Inc.V held $563.12 K in total assets, $173.56 K in total liabilities, and $389.56 K in total stockholders’ equity. Net working capital was $192.77 K with a current ratio of 2.11x.

Who is the CEO and CFO of Avricore Health Inc.V?

The Chief Executive Officer (CEO) of Avricore Health Inc.V is Rodger Seccombe (Appointed June 4, 2025). The Chief Financial Officer (CFO) is Kiki Smith.

Where is Avricore Health Inc.V headquartered and when was it founded?

Avricore Health Inc.V is headquartered in 1120 – 789 West Pender Street, Vancouver, British Columbia, V6C 1H2, Canada. The company traces its founding/incorporation to British Columbia, Canada. Total disclosed workforce/headcount is 1 (as of December 31, 2025; Executive leadership engaged via consulting agreements).

Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official SEC filing.